Luminex Announces Letter Of Intent To Sell RBM

has announced it has entered into a nonbinding letter of intent to divest its Rules-Based Medicine research and development project (“RBM”) to a newly formed company to be headed by Dr. Mark B. Chandler, Luminex’s current Chairman, President and Chief Executive Officer.

RBM uses the Luminex xMAP(TM) technology to analyze a large number of proteins, metabolites and other substances in the blood of normal and diseased individuals.

Luminex intends to transfer the assets and liabilities of RBM to a newly formed company that will, independent of Luminex, capitalize and fund the development of RBM. In the contemplated transaction, it is anticipated Luminex will receive both a preferred stock and common stock equity interest in the newly formed company.

In addition, Luminex will license certain technology and supply microspheres to the new company.

The parties anticipate execution of definitive agreements later this month.

In connection with the proposed transaction, Dr. Chandler will resign as Chairman, Chief Executive Officer and President of Luminex to be Chairman and Chief Executive Officer of the company acquiring the RBM business.

Dr. Chandler will continue to serve as a director of Luminex and will enter into a one-year consulting agreement with Luminex.

Dr. Chandler stated, “It’s exciting to be able to work on a project as promising as Rules-Based Medicine, and it will be rewarding to join the growing community of scientists using the powerful xMAP technology to advance healthcare worldwide. At the same time, I look forward to working with the new management team in establishing the Luminex laboratory as an industry standard.”

G. Walter Loewenbaum, Chairman of the Executive Committee, stated, “We are grateful for the contributions Mark has made to Luminex since he co-founded the company and wish him great success.  Luminex looks forward to participating in the growth and development of Rules-Based Medicine.”

In connection with the proposed transaction, Mr. Loewenbaum will succeed Dr. Chandler as Chairman of the Board of Directors.Luminex also announced that Thomas W. Erickson has joined Luminex and will serve as Interim President and Chief Executive Officer until finding a permanent replacement for Dr. Chandler.

“Tom has agreed to an initial six- month engagement while the Management Evaluation and Search Committee completes its search for a long-term leader of Luminex. Tom comes to us with great leadership skills and experience in serving in this capacity,” said Mr. Loewenbaum.

Mr. Erickson previously provided similar executive management services as Interim President and Chief Executive Officer of Omega Healthcare Investors, Inc. (NYSE).

“I look forward to leading Luminex during this transition period. This divestiture of RBM is part of the Board’s directive for management to fully focus on the core business of Luminex including our commercialization efforts and further development of strategic partnerships with leaders in the life sciences industry,” said Mr. Erickson.

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry.


Generic drug giant Dragon Pharma is offering:

Obtain Dragon Pharma Labs On-line

Masteron 200

Injectable Anabolic Steroid
Active Constituent: Drostanolone Enanthate
Made by: Dragon Pharma
Amount: 1 X 10 ml (200 mg/ml)

Cut Mix 150 - Bulk Price

Administration: Injection
Prime Chemical Name: Testosterone Propionate, Drostanolone Propionate, Trenbolone Acetate
Made by: Dragon Pharma LLC
Pack: 10 x 10 mL vial (150 mg/mL)
Price: 10 x $52.00

Oxymetholon - Cheap Price

Administration: Oral
Main Ingredient: Oxymetholone
Made by: Dragon Pharmaceutical
Pack: 20 x 100 tablets (50 mg/pastille)
Price: 20 x $57.00

Masteron 100

Injectable Anabolic Steroid
Basal Ingredient: Drostanolone Di-Propionate
Manufacturer: Dragon Pharmaceutical
Unit: 1 X 10 ml (100 mg/ml)

Enantat 400

Injectable Anabolic Steroid
Main Constituent: Testosterone Enanthate
Manufacturer: Dragon Pharma LLC
Unit: 1 X 10 ml (400 mg/ml)

Masteron 100 - Cheap Price

Administration: Injection
Base Ingredient: Drostanolone Di-Propionate
Producer: Dragon Pharma Labs
Package: 20 x 10 mL vial (100 mg/mL)
Price: 20 x $42.00

TriTren 150 - Cheap Price

Administration: Injection
Active Substance: Tri Trenbolone
Made by: Dragon Pharma LLC
Package: 20 x 10 mL vial (150 mg/mL)
Price: 20 x $65.00

Deca 500

Injectable Steroid for Muscle Growth
Main Substance: Nandrolone Decanoate
Produced by: Dragon Pharma
10 mL Sterile Multi-dose Vial (500 mg/mL)

Propionat 100

Injectable Steroid for Muscle Growth
Main Constituent: Testosterone Propionate
Branded by: Dragon Pharma LLC
10 mL Sterile Multi-dose Vial (100 mg/mL)

Cypionat 250

Injectable Steroid for Muscle Growth
Main Chemical Name: Testosterone Cypionate
Produced by: Dragon Pharma Labs
10 mL Sterile Multi-dose Vial (250 mg/mL)


Oral Steroid for Muscle Growth
Basal Ingredient: Oxandrolone
Manufacturer: Dragon Pharma
100 pills (50 mg/pill)

Propionat 100 [10 Vials]

Injectable Steroid for Muscle Growth
Prime Chemical Name: Testosterone Propionate
Manufacturer: Dragon Pharma LLC
10 Vials [10 mL per Vial (100 mg/ml)]
Price: 10 x $30.00 = $300.00 in Total